352,569 Shares in Genmab A/S (NASDAQ:GMAB) Bought by DDD Partners LLC

DDD Partners LLC purchased a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 352,569 shares of the company's stock, valued at approximately $8,860,000. DDD Partners LLC owned approximately 0.05% of Genmab A/S as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of GMAB. Russell Investments Group Ltd. raised its holdings in shares of Genmab A/S by 137.7% in the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock worth $28,000 after buying an additional 544 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Genmab A/S by 2.3% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 27,755 shares of the company's stock valued at $830,000 after buying an additional 633 shares during the last quarter. GAMMA Investing LLC lifted its stake in Genmab A/S by 194.0% during the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company's stock valued at $34,000 after acquiring an additional 749 shares during the period. Grandfield & Dodd LLC boosted its holdings in shares of Genmab A/S by 3.4% in the 1st quarter. Grandfield & Dodd LLC now owns 26,418 shares of the company's stock valued at $790,000 after acquiring an additional 860 shares during the last quarter. Finally, Gallacher Capital Management LLC increased its stake in shares of Genmab A/S by 17.9% in the first quarter. Gallacher Capital Management LLC now owns 7,865 shares of the company's stock worth $235,000 after acquiring an additional 1,192 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Trading Down 0.0 %

GMAB traded down $0.01 on Monday, hitting $27.80. 347,100 shares of the company's stock were exchanged, compared to its average volume of 581,413. The firm has a 50-day moving average price of $26.85 and a 200-day moving average price of $28.17. The stock has a market cap of $18.38 billion, a price-to-earnings ratio of 23.17, a P/E/G ratio of 0.88 and a beta of 0.97. Genmab A/S has a fifty-two week low of $24.53 and a fifty-two week high of $39.53.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The company had revenue of $779.50 million during the quarter, compared to analysts' expectations of $734.60 million. On average, equities analysts predict that Genmab A/S will post 1.21 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on GMAB. Royal Bank of Canada upgraded shares of Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Tuesday, August 27th. Truist Financial boosted their price objective on Genmab A/S from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Tuesday, June 4th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Finally, BTIG Research boosted their price target on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a "buy" rating in a report on Thursday, June 27th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Genmab A/S currently has a consensus rating of "Hold" and an average price target of $49.50.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.